계명대학교 의학도서관 Repository

Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin

Metadata Downloads
Author(s)
Hyoeun KimChan Joo LeeDonghoon ChoiByeong-Keuk KimIn-Cheol KimJung-Sun KimChul-Min AhnGeu-Ru HongIn-Jeong ChoChi-Young ShimSang-Hak Lee
Keimyung Author(s)
Kim, In Cheol
Department
Dept. of Internal Medicine (내과학)
Journal Title
지질·동맥경화학회지
Issued Date
2020
Volume
9
Issue
2
Keyword
Rosuvastatin calciumCholesterolLDLBlood pressureHematologyAlanine transaminase
Abstract
Objective:
The aim of this study was to investigate whether a new generic rosuvastatin is non-inferior to a proprietary one in terms of lipid-lowering efficacy. We also evaluated its non-lipid effects including adverse events.

Methods:
One-hundred and fifty-eight patients with cardiovascular risks requiring pharmacological lipid-lowering therapy were screened. After a 4-week run-in period, 126 individuals who met the lipid criteria for drug therapy were randomly assigned to receive the new generic or proprietary rosuvastatin 10 mg daily for 8 weeks. The primary outcome variables were low-density lipoprotein-cholesterol (LDL-C) reduction and LDL-C target achievement. Hematological and biochemical parameters and adverse events were assessed.

Results:
After 8 weeks of drug treatment, the mean percentage change in LDL-C was not different between the groups (−45.5%±19.9% and −45.1%±19.0% for generic and proprietary rosuvastatin, respectively; p=0.38). The LDL-C target achievement rate was similar between the groups (75.0% and 77.1% for generic and proprietary rosuvastatin, respectively; p=0.79). The percentage change in the other lipid profiles was not significantly different. Although generic- and proprietary rosuvastatins modestly affected creatine kinase and blood pressure, respectively, the changes were all within normal ranges. Incidence of adverse events did not differ between the receivers of the 2 formulations.

Conclusion:
The new generic rosuvastatin was non-inferior to the proprietary rosuvastatin in terms of lipid-lowering efficacy. The rosuvastatin formulations did not exhibit clinically significant non-lipid effects with good safety profiles. Our study provides comprehensive data regarding 2 rosuvastatin formulations in East Asian subjects.
Keimyung Author(s)(Kor)
김인철
Publisher
School of Medicine (의과대학)
Citation
Hyoeun Kim et al. (2020). Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin. 지질·동맥경화학회지, 9(2), 283–290. doi: 10.12997/jla.2020.9.2.283
Type
Article
ISSN
2288-2561
Source
https://e-jla.org/DOIx.php?id=10.12997/jla.2020.9.2.283
DOI
10.12997/jla.2020.9.2.283
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42795
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.